EAU guidelines upgrade Aquablation therapy to strong surgical recommendation for benign prostatic hyperplasia – PROCEPT BioRobotics
PROCEPT BioRobotics highlighted the latest update to the European Association of Urology (EAU) Guidelines for male lower urinary tract symptoms (LUTS), which include an upgrade of Aquablation therapy to a strong recommendation as a surgical treatment option for men with benign prostatic hyperplasia (BPH).
The EAU guidelines are widely regarded as one of the most rigorous and influential clinical guideline frameworks in urology globally. The updated guidelines now strongly recommend offering Aquablation therapy as an alternative to transurethral resection of the prostate (TURP) for men with moderate-to-severe urinary symptoms due to BPH, particularly for patients interested in preserving ejaculatory function. This upgrade indicates strong evidence quality and a favorable balance between benefit, harm, and patient preference.
Guidelines are supported by outcomes from multiple clinical trials on Aquablation therapy, including WATER, a randomized trial against TURP, and WATER II trials demonstrating durable improvements in urinary symptoms and preservation of sexual and urinary function. The guidelines also now recognize evidence supporting Aquablation therapy across a broad range of prostate anatomies, including larger prostate glands, with additional evidence continuing to emerge from recently published studies such as WATER III, a randomized trial against laser enucleation in large glands.
“The strength of the clinical evidence supporting Aquablation therapy continues to grow, and this guideline upgrade from the European Association of Urology represents an important milestone for Aquablation therapy,” said Larry Wood, President and Chief Executive Officer of PROCEPT BioRobotics.
“A strong recommendation from one of the most respected global guideline bodies reflects the strength of the clinical evidence supporting Aquablation therapy and reinforces its role as a modern surgical option for physicians seeking to deliver durable symptom relief while preserving quality-of-life outcomes that matter most to patients,” said Dr. Evangelos Liatsikos, Professor of Urology and Chairman of the Department of Urology at the University of Patras, Greece, and Chairman of the European School of Urology (ESU).
Recognition from the EAU adds to growing international clinical validation for Aquablation therapy, including support from health technology assessment bodies such as the National Institute for Health and Care Excellence (NICE) in the United Kingdom supporting the routine use of Aquablation therapy within the NHS.
